Cancer Cell
Volume 36, Issue 4, 14 October 2019, Pages 431-443.e5
ArticleCombining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
Under an Elsevier user license
open archive
Keywords
asciminib
ABL001
allosteric inhibitors
chronic myeloid leukemia
ponatinib
targeted therapy
compound mutation
Cited by (0)
© 2019 Elsevier Inc.